Current Treatment Scenario and Emerging Therapies:
How many companies are developing ONCOLYTIC VIRUS drugs?
How many ONCOLYTIC VIRUS drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ONCOLYTIC VIRUS?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ONCOLYTIC VIRUS therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for ONCOLYTIC VIRUS and their status?
What are the key designations that have been granted to the emerging and approved drugs?
Key Players
Genelux Corporation
Candel Therapeutics
CG Oncolgy
DNAtrix
SillaJen Biotherapeutics
Oncolytics Biotech
Wuhan Binhui Biotechnology
Oryx GmbH
Jiangsu Sinorda Biomedicine Co., Ltd
Virogin Biotech
Replimune
Viralytics
Oncolys Biopharma
Istari Oncology
Immvira Pharma
Seneca Therapeutics
Treovir, LLC
Targovax
Lokon Pharma
ORCA Therapeutics
Beijing SyngenTech
ViruCure
Tasly Pharmaceuticals
Turnstone Biologics
BioInvent
Transgene
Elicera Therapeutics
Orgenesis
Virttu Biologics
Imugene
Astellas Pharma
Wuhan Binhui Biotechnology Co., Ltd.
Mustang Bio
Virogin Biotech
Vaxiion Therapeutics
ImmVirX
Memgen
Replimune
Immvira Pharma
ViroCure
GeneMedicine
PsiOxus Therapeutics
VCN Biosciences
Candel therapeutics
Sorrento Therapeutics
Imugene Limited
Calidi Biotherapeutics
Replimune
TILT Biotherapeutics
Guangzhou Virotech Pharmaceutical
DNAtrix
Oncorus
BioEclipse Therapeutics
IMU Price at posting:
13.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)